See more : Ironwood Pharmaceuticals, Inc. (IRWD) Income Statement Analysis – Financial Results
Complete financial analysis of Humana Inc. (HUM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Humana Inc., a leading company in the Medical – Healthcare Plans industry within the Healthcare sector.
You may be interested
- IFB Industries Limited (IFBIND.BO) Income Statement Analysis – Financial Results
- Hyundai Construction Equipment Co., Ltd. (267270.KS) Income Statement Analysis – Financial Results
- Cystech Electronics Corp. (6651.TWO) Income Statement Analysis – Financial Results
- China Art Financial Holdings Limited (CHFHF) Income Statement Analysis – Financial Results
- Iluka Resources Limited (ILU.AX) Income Statement Analysis – Financial Results
Humana Inc. (HUM)
About Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, and home solutions services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2021, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 106.37B | 92.87B | 83.06B | 77.16B | 64.89B | 56.91B | 53.77B | 54.38B | 54.29B | 48.50B | 41.31B | 39.13B | 36.83B | 33.87B | 30.96B | 28.95B | 25.29B | 21.42B | 14.42B | 13.10B | 12.23B | 11.26B | 10.19B | 10.51B | 10.11B | 9.78B | 8.04B | 6.79B | 4.70B | 3.65B | 3.14B | 4.04B | 5.87B | 4.85B |
| Cost of Revenue | 13.19B | 12.67B | 10.12B | 10.05B | 7.38B | 7.53B | 6.57B | 7.28B | 7.32B | 7.64B | 6.36B | 5.83B | 5.40B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 93.19B | 80.20B | 72.94B | 67.10B | 57.51B | 49.39B | 47.20B | 47.10B | 46.97B | 40.86B | 34.96B | 33.30B | 31.44B | 33.87B | 30.96B | 28.95B | 25.29B | 21.42B | 14.42B | 13.10B | 12.23B | 11.26B | 10.19B | 10.51B | 10.11B | 9.78B | 8.04B | 6.79B | 4.70B | 3.65B | 3.14B | 4.04B | 5.87B | 4.85B |
| Gross Profit Ratio | 87.60% | 86.36% | 87.82% | 86.97% | 88.63% | 86.78% | 87.79% | 86.62% | 86.52% | 84.25% | 84.62% | 85.10% | 85.35% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.40B | 4.66B | 4.23B | 3.94B | 3.48B | 3.02B | 2.18B | 1.88B | 1.86B | 1.74B | 1.55B | 1.44B | 1.37B | 1.33B | 1.12B | 940.00M | 571.00M | 436.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 12.20B | 10.12B | 10.05B | 7.38B | 7.53B | 6.42B | 7.17B | 7.30B | 7.64B | 6.36B | 5.83B | 5.40B | 4.66B | 4.23B | 3.94B | 3.48B | 3.02B | 2.18B | 1.88B | 1.86B | 1.74B | 1.55B | 1.44B | 1.37B | 1.33B | 1.12B | 940.00M | 571.00M | 436.00M | 368.00M | 371.00M | 226.00M | 226.40M |
| Other Expenses | 102.36B | 76.87B | 69.20B | 62.15B | 53.80B | 47.10B | 43.09B | 45.47B | 44.38B | 38.50B | 32.90B | 31.28B | 29.09B | 27.08B | 24.81B | 23.93B | 20.46B | 17.57B | 11.80B | 10.79B | 10.01B | -12.77B | 8.44B | 8.93B | -11.85B | -10.86B | -8.86B | -7.70B | -4.97B | -3.81B | -3.36B | -4.11B | -5.44B | -4.48B |
| Operating Expenses | 102.36B | 89.07B | 79.32B | 72.20B | 61.18B | 54.62B | 49.51B | 52.64B | 51.67B | 46.14B | 39.25B | 37.11B | 34.49B | 31.74B | 29.04B | 27.87B | 23.93B | 20.59B | 13.98B | 12.67B | 11.86B | -11.03B | 9.99B | 10.37B | -10.48B | -9.53B | -7.75B | -6.76B | -4.40B | -3.37B | -2.99B | -3.74B | -5.21B | -4.25B |
| Cost & Expenses | 102.36B | 89.07B | 79.32B | 72.20B | 61.18B | 54.62B | 49.51B | 52.64B | 51.67B | 46.14B | 39.25B | 37.11B | 34.60B | 32.12B | 29.36B | 27.95B | 24.00B | 20.65B | 14.00B | 12.69B | 11.88B | 11.05B | 10.01B | 10.40B | 10.52B | 9.58B | 7.77B | 6.77B | 4.41B | 3.40B | 422.00M | 680.00M | 579.00M | 568.60M |
| Interest Income | 0.00 | 401.00M | 326.00M | 283.00M | 242.00M | 218.00M | 242.00M | 189.00M | 186.00M | 192.00M | 140.00M | 105.00M | 0.00 | 60.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 493.00M | 401.00M | 326.00M | 283.00M | 242.00M | 218.00M | 242.00M | 189.00M | 186.00M | 192.00M | 140.00M | 105.00M | 109.00M | 105.06M | 105.84M | 80.29M | 68.88M | 63.14M | 39.32M | 23.17M | 17.37M | 17.25M | 25.30M | 29.00M | 33.00M | 47.00M | 20.00M | 11.00M | 11.00M | 25.00M | 7.00M | 71.00M | 97.00M | 111.30M |
| Depreciation & Amortization | 917.00M | 845.00M | 713.00M | 616.00M | 575.00M | 534.00M | 485.00M | 465.00M | 447.00M | 449.00M | 426.00M | 338.00M | 303.00M | 262.91M | 250.27M | 220.35M | 184.81M | 148.60M | 128.86M | 117.79M | 126.78M | 120.73M | 171.02M | 147.00M | 124.00M | 128.00M | 108.00M | 98.00M | 70.00M | 50.00M | 47.00M | 238.00M | 256.00M | 230.90M |
| EBITDA | 4.93B | 4.68B | 4.34B | 5.45B | 4.17B | 2.85B | 4.75B | 2.21B | 3.06B | 2.81B | 2.49B | 2.35B | 2.54B | 2.12B | 1.85B | 1.29B | 1.47B | 910.68M | 550.57M | 533.64M | 488.86M | 347.92M | 369.91M | 290.00M | -247.45M | 331.00M | 128.00M | 116.00M | 81.00M | 307.00M | 54.00M | 309.00M | 353.00M | 342.20M |
| EBITDA Ratio | 4.63% | 5.00% | 5.37% | 7.22% | 6.61% | 4.97% | 8.83% | 4.06% | 5.64% | 5.80% | 6.02% | 6.02% | 6.89% | 5.94% | 5.98% | 4.19% | 5.83% | 4.25% | 3.82% | 4.07% | 3.86% | 2.94% | 3.47% | 2.48% | -2.77% | 3.38% | 4.70% | 1.71% | 7.61% | 8.40% | 88.05% | 89.07% | 94.49% | 93.04% |
| Operating Income | 4.01B | 3.80B | 3.75B | 4.96B | 3.71B | 2.29B | 4.26B | 1.74B | 2.62B | 2.36B | 2.06B | 2.02B | 2.24B | 1.75B | 1.60B | 992.85M | 1.29B | 762.09M | 421.71M | 415.85M | 344.72M | 209.93M | 183.08M | 114.00M | -404.00M | 203.00M | 270.00M | 18.00M | 288.00M | 257.00M | 2.72B | 3.36B | 5.29B | 4.28B |
| Operating Income Ratio | 3.77% | 4.09% | 4.51% | 6.42% | 5.72% | 4.03% | 7.93% | 3.20% | 4.82% | 4.87% | 4.99% | 5.15% | 6.07% | 5.17% | 5.17% | 3.43% | 5.10% | 3.56% | 2.92% | 3.17% | 2.82% | 1.86% | 1.80% | 1.08% | -3.99% | 2.08% | 3.36% | 0.27% | 6.13% | 7.03% | 86.55% | 83.18% | 90.13% | 88.28% |
| Total Other Income/Expenses | -630.00M | -232.00M | -391.00M | -386.00M | 264.00M | -1.04B | -242.00M | -189.00M | 84.00M | -192.00M | -140.00M | -105.00M | 5.29B | -105.06M | -105.84M | -80.29M | -68.69M | -63.45M | -20.41M | -23.17M | 0.00 | 0.00 | 0.00 | 0.00 | -404.84M | 203.08M | 0.00 | 0.00 | 0.00 | 257.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 3.38B | 3.57B | 3.35B | 4.60B | 3.46B | 2.06B | 4.02B | 1.55B | 2.43B | 2.17B | 1.92B | 1.91B | 2.24B | 1.75B | 1.60B | 992.85M | 1.29B | 762.09M | 421.71M | 415.85M | 344.72M | 209.93M | 183.08M | 114.00M | -404.00M | 203.00M | 270.00M | 18.00M | 288.00M | 257.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 3.18% | 3.84% | 4.04% | 5.96% | 5.33% | 3.62% | 7.48% | 2.85% | 4.48% | 4.47% | 4.65% | 4.88% | 6.07% | 5.17% | 5.17% | 3.43% | 5.10% | 3.56% | 2.92% | 3.17% | 2.82% | 1.86% | 1.80% | 1.08% | -3.99% | 2.08% | 3.36% | 0.27% | 6.13% | 7.03% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 836.00M | 762.00M | 485.00M | 1.31B | 763.00M | 391.00M | 1.57B | 938.00M | 1.16B | 1.02B | 690.00M | 689.00M | 816.00M | 650.17M | 562.09M | 345.69M | 455.62M | 274.66M | 113.23M | 135.84M | 115.78M | 67.18M | 65.91M | 24.00M | -22.00M | 74.00M | 97.00M | 6.00M | 98.00M | 81.00M | 54.00M | 109.00M | 200.00M | 180.50M |
| Net Income | 2.49B | 2.81B | 2.93B | 3.37B | 2.71B | 1.68B | 2.45B | 614.00M | 1.28B | 1.15B | 1.23B | 1.22B | 1.42B | 1.10B | 1.04B | 647.15M | 833.68M | 487.42M | 308.48M | 280.01M | 228.93M | 142.76M | 117.17M | 90.00M | -382.00M | 129.00M | 173.00M | 12.00M | 190.00M | 176.00M | 89.00M | 122.70M | 355.00M | 309.60M |
| Net Income Ratio | 2.34% | 3.02% | 3.53% | 4.36% | 4.17% | 2.96% | 4.55% | 1.13% | 2.35% | 2.36% | 2.98% | 3.12% | 3.85% | 3.25% | 3.36% | 2.24% | 3.30% | 2.28% | 2.14% | 2.14% | 1.87% | 1.27% | 1.15% | 0.86% | -3.78% | 1.32% | 2.15% | 0.18% | 4.04% | 4.82% | 2.84% | 3.03% | 6.05% | 6.38% |
| EPS | 20.09 | 22.20 | 22.79 | 25.47 | 20.20 | 12.24 | 16.94 | 4.11 | 8.54 | 7.44 | 7.81 | 7.56 | 8.58 | 6.55 | 6.21 | 3.87 | 5.00 | 2.97 | 1.91 | 1.75 | 1.41 | 0.85 | 0.71 | 0.54 | -2.28 | 0.77 | 1.06 | 0.07 | 1.17 | 1.10 | 0.56 | 0.77 | 2.26 | 3.00 |
| EPS Diluted | 20.00 | 22.08 | 22.67 | 25.31 | 20.10 | 12.16 | 16.81 | 4.07 | 8.44 | 7.36 | 7.73 | 7.47 | 8.46 | 6.47 | 6.15 | 3.83 | 4.91 | 2.90 | 1.87 | 1.72 | 1.38 | 0.83 | 0.70 | 0.54 | -2.28 | 0.77 | 1.05 | 0.07 | 1.16 | 1.10 | 0.55 | 0.77 | 2.26 | 3.00 |
| Weighted Avg Shares Out | 123.87M | 126.42M | 128.69M | 132.20M | 134.05M | 137.49M | 144.49M | 149.37M | 149.45M | 154.19M | 157.50M | 161.48M | 165.41M | 167.78M | 167.36M | 167.17M | 166.87M | 164.12M | 161.51M | 160.01M | 158.68M | 167.95M | 165.03M | 166.76M | 167.73M | 167.48M | 163.41M | 162.53M | 162.27M | 160.00M | 158.93M | 159.35M | 157.08M | 101.13M |
| Weighted Avg Shares Out (Dil) | 124.44M | 127.09M | 129.40M | 133.01M | 134.73M | 138.40M | 145.58M | 150.92M | 151.14M | 155.87M | 159.15M | 163.46M | 167.83M | 169.80M | 169.07M | 168.97M | 169.82M | 168.08M | 164.96M | 162.80M | 162.13M | 171.99M | 167.39M | 166.76M | 167.73M | 167.48M | 165.84M | 165.28M | 164.59M | 160.79M | 161.82M | 159.35M | 157.08M | 101.13M |
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humana Inc. - HUM
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. ("Humana" or the "Company") (NYSE:HUM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Humana's Payouts Will Get a Hard Look. Why the Election Matters More Than Earnings.
The health insurer's third-quarter report comes Wednesday. The numbers will show the growing problems with Medicare Advantage.
HUM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Humana Inc. and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)---- $HUM #Humana--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Humana Inc. (“Humana” or “the Company”) (NYSE: HUM). Investors who purchased Humana securities are encouraged to obtain additional information and assist...
Will Higher Expense Level Be a Woe for Humana in Q3 Earnings?
HUM's Q3 results are likely to suffer from decline in commercial fully-insured premiums and higher operating costs, partly offset by a well-performing Medicare business.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Humana Inc. (HUM) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / October 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Humana Inc. ("Humana" or "the Company") (NYSE:HUM). Investors who purchased Humana securities are encouraged to...
Cigna Considers Humana Acquisition – What It Means for the Stocks
There has been speculation of a massive merger in the medical sector between two massive health insurers. Specifically, the rumor is The Cigna Group NYSE: CI is interested in acquiring Humana Inc. NYSE: HUM.
HUM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Humana Inc. and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)---- $HUM #Humana--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Humana Inc. (“Humana” or “the Company”) (NYSE: HUM). Investors who purchased Humana securities are encouraged to obtain additional information and assist...
What Analyst Projections for Key Metrics Reveal About Humana (HUM) Q3 Earnings
Evaluate the expected performance of Humana (HUM) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humana Inc. - HUM
NEW YORK, NY / ACCESSWIRE / October 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. ("Humana" or the "Company") (NYSE:HUM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
HUM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Humana Inc. and Encourages Investors to Contact the Firm
NEW YORK, Oct. 27, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Humana Inc. (“Humana” or “the Company”) (NYSE: HUM). Investors who purchased Humana securities are encouraged...
Source: https://incomestatements.info
Category: Stock Reports